Anti-H3L Antibody (NAL_A185)
Anti-H3L Antibody (NAL_A185) is a neutralizing antibody targeting the H3L envelope protein of vaccinia virus (CV) belonging to the genus Orthopoxvirus. By binding to the H3L protein of intracellular mature virions, Anti-H3L Antibody (NAL_A185) blocks the binding of the virus to host cells, thereby neutralizing viral infectivity. Anti-H3L Antibody (NAL_A185) not only protects BALB/c mice from intranasal challenge with the lethal vaccinia virus WR strain, reducing weight loss and mortality, but also exhibits complement-dependent neutralizing activity against monkeypox virus. Among these properties, NAL_A185 is an immune target induced by the smallpox vaccine Dryvax; it elicits a robust recall antibody response and induces high-titer neutralizing antibodies in mice. Anti-H3L Antibody (NAL_A185) can be used for studies related to vaccinia virus infection, monkeypox and monkeypox disease.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Affinity-purified human Anti-H3L Antibody (44 μg/mL; 16-18 h virus-antibody incubation, 2 days total assay) potently neutralizes vaccinia virus strain WR in CV-1 cells with a PRNT50 of 44 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (7-week-old)[2]
-
Dosage:50 μg MBP-H3L (immunization); 50 μg MBP-H3L (final booster)
-
Administration:i.p.; four times at 2-week intervals (immunization); single dose (final booster)
-
Result:Induced a strong MBP-H3L-specific antibody response, with significantly elevated antibody levels detected in serum collected 49 days after the first immunization.
Bound to residues 35-89 of MPXV H3L.
Cross-reacted with H3L in MPXV and VACV virions.
Exhibited complement-dependent neutralizing activity against MPXV.
Format
-
Product Image
Chemical Information
-
SMILES
[Anti-H3L Antibody (NAL_A185)]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Davies DH, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol. 2005;79(18):11724-11733. [Content Brief]
[2]. Huang IH, et al. Monkeypox virus H3L protein as the target antigen for developing neutralizing antibody and serological assay. Appl Microbiol Biotechnol. 2025;109(1):80. Published 2025 Apr 2. [Content Brief]
[3]. Yefet R, et al. Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens. iScience. 2023;26(2):105957. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-H3L Antibody (NAL_A185) Related Classifications
HY-P992081 Related Classifications
Powered by Bioz
Keywords